Condition: Ulcerative Colitis (UC) · Ulcerative Colitis (Disorder) · Ulcerative Colitis Acute · Sponsor: Benethera (Shaoxing) Biotechnology Co., Ltd.
A Phase 1, 2-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, and PK of single, ascending oral doses (SAD) of BDHK-2009 (Part 1) and multiple oral doses (Part 2) of BDHK-200 in healthy adult participants.
This description comes directly from the study's public registry record.
Shuang Zhang · +86-010-82146616 · zhangshuang@benethera.com
Always discuss trial participation with your own doctor first.
| Zhejiang Xiaoshan Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07632573